Copyright
©The Author(s) 2023.
World J Gastroenterol. May 28, 2023; 29(20): 3133-3144
Published online May 28, 2023. doi: 10.3748/wjg.v29.i20.3133
Published online May 28, 2023. doi: 10.3748/wjg.v29.i20.3133
Table 1 Clinicodemographic characteristics of the study patients, n (%)
Characteristic | Total No. of patients (n = 68) | Number of prior eradication failures | ||
1 (n = 47) | 2 (n = 15) | 3 (n = 6) | ||
Sex (male) | 20 (29.4) | 10 (21.3) | 6 (4.0) | 4 (66.7) |
Age (yr), mean ± SD | 49.60 ± 10.57 | 49.94 ± 10.00 | 48.87 ± 12.65 | 48.83 ± 11.27 |
Height (m), mean ± SD | 1.63 ± 0.07 | 1.62 ± 0.09 | 1.64 ± 0.08 | 1.68 ± 0.10 |
Weight (kg), mean ± SD | 59.52 ± 12.30 | 56.83 ± 12.19 | 63.80 ± 9.94 | 69.92 ± 11.50 |
BMI (kg/m2), mean ± SD | 22.31 ± 3.64 | 21.59 ± 3.98 | 23.63 ± 2.04 | 24.63 ± 1.80 |
Lifestyle factors | ||||
Smoking | 5 (7.3) | 4 (8.5) | 0 (0) | 1 (16.7) |
Drinking | 4 (5.9) | 0 (0) | 1 (6.7) | 3 (50.0) |
Symptom | ||||
Abdominal pain | 7 (10.3) | 5 (10.6) | 2 (13.3) | 0 (0) |
Bloating | 6 (8.8) | 4 (8.5) | 2 (13.3) | 0 (0) |
Diarrhea | 1 (1.5) | 0 (0) | 1 (6.7) | 0 (0) |
Halitosis | 1 (1.5) | 1 (2.1) | 0 (0) | 0 (0) |
Belching | 13 (19.1) | 8 (17.0) | 3 (20.0) | 2 (33.4) |
Nausea | 2 (2.9) | 2 (4.3) | 0 (0) | 0 (0) |
Bitter taste | 1 (1.5) | 1 (2.1) | 0 (0) | 0 (0) |
Asymptomatic | 37 (54.4) | 26 (55.3) | 7 (46.7) | 4 (66.7) |
Concomitant disease | ||||
Diabetes mellitus | 9 (13.2) | 8 (17.0) | 1 (6.7) | 0 (0) |
Hypertension | 14 (20.6) | 7 (14.9) | 5 (33.3) | 2 (33.4) |
Anxiety disorder | 4 (5.9) | 1 (2.1) | 2 (13.3) | 1 (16.7) |
Gastroscopy findings | ||||
Atrophic gastritis | 33 (48.6) | 27 (57.4) | 4 (26.7) | 2 (33.4) |
Non-atrophic gastritis | 24 (35.3) | 14 (29.8) | 8 (53.3) | 2 (33.4) |
Peptic ulcer | 4 (5.9) | 1 (2.1) | 1 (6.7) | 2 (33.4) |
Polyp | 1 (1.5) | 0 (0) | 1 (6.7) | 0 (0) |
Not applicable (no gastroscopy done) | 6 (8.9) | 5 (10.6) | 1 (13.3) | 0 (0) |
Table 2 Factors potentially influencing Helicobacter pylori eradication, n (%)
Factor | Eradication failure (n = 5) | Successful eradication (n = 63) | P value |
Sex (male) | 2 (40.0) | 18 (28.6) | 0.627 |
Age (yr), mean ± SD | 54.40 ± 5.86 | 49.22 ± 10.80 | 0.295 |
Height (m), mean ± SD | 1.62 ± 0.10 | 1.62 ± 0.07 | 0.778 |
Weight (kg), mean ± SD | 64.60 ±11.42 | 59.12 ± 12.37 | 0.129 |
BMI (kg/m2), mean ± SD | 24.43 ± 1.88 | 22.14 ± 3.70 | 0.112 |
Concomitant disease | |||
Diabetes mellitus | 1 (20.0) | 8 (12.7) | 0.520 |
Hypertension | 1 (20.0) | 13 (20.6) | 1.000 |
Anxiety disorder | 2 (40.0) | 2 (3.2) | 0.025 |
Gastroscopy findings | |||
Atrophic gastritis | 2 (40.0) | 31 (49.2) | 1.000 |
Non-atrophic gastritis | 3 (60.0) | 21 (33.3) | 0.337 |
Peptic ulcer | 0 (0.0) | 4 (6.3) | 1.000 |
Polyp | 0 (0.0) | 1 (1.6) | 1.000 |
No. of prior treatments | |||
1 | 3 (60.0) | 44 (69.8) | 0.641 |
≥ 2 | 2 (40.0) | 19 (30.2) |
Table 3 Adverse events and patient compliance
Variable | % |
Adverse events | |
Total adverse events | 14.7% (10/68) |
Dry mouth | 1.5% (1/68) |
Skin rash | 4.4% (3/68) |
Bloating | 1.5% (1/68) |
Diarrhea | 5.9% (4/68) |
Abdominal pain | 1.5% (1/68) |
Grade of adverse event | |
Mild | 70.0% (7/10) |
Moderate | 30.0% (3/10) |
Severe | 0% (0/10) |
1Compliance | |
Good | 95.6% (65/68) |
Poor | 4.4% (3/68) |
Table 4 Comparison of liver and kidney function before and after treatment
Characteristic | Before (n = 41) | After (n = 41) | P value |
Total bilirubin (μmol/L), mean ± SD | 13.68 ± 4.82 | 14.96 ± 5.22 | 0.252 |
ALT (U/L), mean ± SD | 16.92 ± 8.33 | 21.46 ± 16.03 | 0.270 |
AST (U/L), mean ± SD | 18.99 ± 7.61 | 21.03 ± 10.67 | 0.670 |
Creatinine (μmol/L), mean ± SD | 60.105 ± 12.060 | 60.53 ± 11.35 | 0.974 |
- Citation: Yu J, Lv YM, Yang P, Jiang YZ, Qin XR, Wang XY. Safety and effectiveness of vonoprazan-based rescue therapy for Helicobacter pylori infection. World J Gastroenterol 2023; 29(20): 3133-3144
- URL: https://www.wjgnet.com/1007-9327/full/v29/i20/3133.htm
- DOI: https://dx.doi.org/10.3748/wjg.v29.i20.3133